Prothena Corporation PLC
NASDAQ:PRTA

Watchlist Manager
Prothena Corporation PLC Logo
Prothena Corporation PLC
NASDAQ:PRTA
Watchlist
Price: 16.1 USD -6.56% Market Closed
Market Cap: 865.9m USD
Have any thoughts about
Prothena Corporation PLC?
Write Note

Relative Value

The Relative Value of one PRTA stock under the Base Case scenario is 44.76 USD. Compared to the current market price of 16.1 USD, Prothena Corporation PLC is Undervalued by 64%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PRTA Relative Value
Base Case
44.76 USD
Undervaluation 64%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
95
vs Industry
39
Median 3Y
13.4
Median 5Y
51.5
Industry
8.1
Forward
5.9
vs History
vs Industry
Median 3Y
-18.6
Median 5Y
-9.4
Industry
23
Forward
-6.8
vs History
vs Industry
Median 3Y
-11.2
Median 5Y
-9.1
Industry
23.4
vs History
vs Industry
Median 3Y
-10.9
Median 5Y
-8.9
Industry
27.3
vs History
90
vs Industry
36
Median 3Y
3.5
Median 5Y
3.2
Industry
2.6
vs History
92
vs Industry
44
Median 3Y
9.2
Median 5Y
34
Industry
8.1
Forward
2.1
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.6
vs History
vs Industry
Median 3Y
-7
Median 5Y
-4.2
Industry
4.3
Forward
-1.7
vs History
vs Industry
Median 3Y
-7
Median 5Y
-4.1
Industry
3.8
Forward
-1.9
vs History
vs Industry
Median 3Y
-6.4
Median 5Y
-3.8
Industry
6
vs History
vs Industry
Median 3Y
-6.2
Median 5Y
-3.7
Industry
3.8
vs History
69
vs Industry
20
Median 3Y
33.9
Median 5Y
23.1
Industry
4.8

Multiples Across Competitors

PRTA Competitors Multiples
Prothena Corporation PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IE
Prothena Corporation PLC
NASDAQ:PRTA
865.7m USD 4 -17 -3.3 -3.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 678 545.3 -179 080.5 -217 460.8 -214 979.3
US
Abbvie Inc
NYSE:ABBV
299.8B USD 5.4 59 14.8 22.7
US
Amgen Inc
NASDAQ:AMGN
159.1B USD 4.9 37.6 17.5 33.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
124.7B USD 11.7 -259.9 26.3 27.6
US
Gilead Sciences Inc
NASDAQ:GILD
114.8B USD 4.1 910.9 10.1 10.1
US
Epizyme Inc
F:EPE
94.1B EUR 1 869.7 -477.1 -519.6 -505.7
AU
CSL Ltd
ASX:CSL
137.3B AUD 6 33.5 20.7 25.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
86.2B USD 6.2 18.5 17 18.9
US
Seagen Inc
F:SGT
39.3B EUR 18 -55.2 -59.4 -53.6
NL
argenx SE
XBRU:ARGX
34B EUR 18.4 -129.2 -103.9 -75.7
P/E Multiple
Earnings Growth
IE
Prothena Corporation PLC
NASDAQ:PRTA
Average P/E: 211.9
Negative Multiple: -17
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -179 080.5 N/A
US
Abbvie Inc
NYSE:ABBV
59
412%
US
Amgen Inc
NASDAQ:AMGN
37.6
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -259.9
42%
US
Gilead Sciences Inc
NASDAQ:GILD
910.9
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -477.1 N/A
AU
CSL Ltd
ASX:CSL
33.5
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.5
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.2 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.2 N/A
EV/EBITDA Multiple
EBITDA Growth
IE
Prothena Corporation PLC
NASDAQ:PRTA
Average EV/EBITDA: 17.7
Negative Multiple: -3.3
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 460.8 N/A
US
Abbvie Inc
NYSE:ABBV
14.8
28%
US
Amgen Inc
NASDAQ:AMGN
17.5
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.3
38%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -519.6 N/A
AU
CSL Ltd
ASX:CSL
20.7
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.4 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -103.9 N/A
EV/EBIT Multiple
EBIT Growth
IE
Prothena Corporation PLC
NASDAQ:PRTA
Average EV/EBIT: 23
Negative Multiple: -3.3
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -214 979.3 N/A
US
Abbvie Inc
NYSE:ABBV
22.7
88%
US
Amgen Inc
NASDAQ:AMGN
33.2
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.6
44%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -505.7 N/A
AU
CSL Ltd
ASX:CSL
25.8
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.9
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.6 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -75.7 N/A

See Also

Discover More
Back to Top